Teladoc rises sharply after quarterly results and guidance update

What happened

Teladoc (TDOC) rose 26.9% on October 29, 2026, because of its third-quarter results and an upgraded full-year GAAP outlook. The company reported third-quarter consolidated revenue of $605 million and a GAAP loss per share of $0.15 on October 28, 2026, versus a loss of $0.21 a year earlier. Management said growth in Integrated Care and insurance-covered BetterHelp revenue helped offset pressure in BetterHelp's cash-pay business, and the firm raised its full-year GAAP earnings-per-share outlook after the report.

How big was the move

The stock closed at $8.73 on heavy trading, with volume 5.2 times its 20-day average and an opening that was 15.1% above the previous close. The one-day gain of 26.9% was 6.4 times a typical daily move for this stock and left the five-session change at a rise of 38.1%. On the day the S&P 500 fell 0.3% and the healthcare sector median rose 0.5%, so the stock outperformed its sector by 26.4 percentage points.

The technical picture

Technically, the stock was trading well above its short- and medium-term averages, with the closing price 42.5% above its 20-day moving average and 41.0% above its 50-day moving average. It was also 35.1% above its 200-day moving average, while the 50-day average remained below the 200-day average, a sign of a weak longer-term trend. Momentum measures showed a Relative Strength Index of 82, above 70 and often called overbought, and the stock sat 11.7% below its 52-week high. The stock had climbed 50.5% over one month and 30.1% over three months, leaving it 4.4% higher than a year ago but 7.6 percentage points behind the S&P 500 over the same period.

Fundamentals and valuation

For the four quarters through September 30, 2026, Teladoc reported revenue of $2.47 billion, a decline of 2.4% from a year earlier. Gross margin improved to 73.2% from 69.8% a year earlier, reflecting an improved mix as insurance-covered services grew. Operating margin narrowed to 6.1% from 10.9% a year earlier, while diluted earnings per share for that trailing four-quarter period was $-0.86. Free-cash-flow margin was 9.4%, return on invested capital was 7.1%, and the balance sheet showed net debt of 0.7 times EBITDA. Share count increased by 3.5% over one year.

Those fundamentals sit against a valuation signal from a free-cash-flow yield of 20.2%, and PromtFinance scoring that places Teladoc at 93 for Value (Exceptional), 72 for Quality (Positive), and 30 for Growth (Weak). The combination points to a business that is generating cash relative to market value but faces slower growth and mixed profitability trends on an operating basis.

Earnings and analyst expectations

Teladoc's last reported quarter on October 28, 2026, showed earnings per share of $-0.15 against $-0.22 expected, which was 31.0% above estimates, and consolidated revenue of $605 million. Adjusted EBITDA exceeded expectations and management highlighted BetterHelp insurance revenue of $32 million in the quarter. The company has beaten estimates in two consecutive quarters and its average surprise over the last four reports was 16.9% above estimates. Typical two-day market reactions after recent reports have been a fall of 0.9%, but the market reaction on October 29 deviated from that pattern.

Analyst coverage remains broad: 42 analysts follow the stock with a consensus price target of $8.83, which is 1.1% above the closing price, and the consensus rating is Hold. Thirty-six percent of analysts rate the stock Buy or Strong Buy. The next scheduled report is February 23, 2027.

What to watch

• February 23, 2027: next scheduled earnings report.
• Progress in Integrated Care and insurance-covered BetterHelp revenue as drivers cited by management in the Q3 call.
• Full-year GAAP earnings-per-share outlook following the raise after the Q3 report.
• Trading volume and volatility trends after the session, given volume was 5.2 times its 20-day average and 60-day volatility is 67% annualized.